- Home
- LEVI vs HALO Comparison
LEVI vs HALO Comparison
Compare LEVI & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEVI
- HALO
- Stock Information
- Founded
- LEVI 1853
- HALO 1998
- Country
- LEVI United States
- HALO United States
- Employees
- LEVI N/A
- HALO N/A
- Industry
- LEVI Apparel
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEVI Consumer Discretionary
- HALO Health Care
- Exchange
- LEVI Nasdaq
- HALO Nasdaq
- Market Cap
- LEVI 6.2B
- HALO 7.4B
- IPO Year
- LEVI 2019
- HALO N/A
- Fundamental
- Price
- LEVI $17.60
- HALO $52.81
- Analyst Decision
- LEVI Strong Buy
- HALO Buy
- Analyst Count
- LEVI 11
- HALO 9
- Target Price
- LEVI $20.45
- HALO $63.56
- AVG Volume (30 Days)
- LEVI 2.1M
- HALO 1.7M
- Earning Date
- LEVI 06-30-2025
- HALO 08-05-2025
- Dividend Yield
- LEVI 2.95%
- HALO N/A
- EPS Growth
- LEVI 195.92
- HALO 55.40
- EPS
- LEVI 0.89
- HALO 3.76
- Revenue
- LEVI $6,401,900,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- LEVI N/A
- HALO $25.77
- Revenue Next Year
- LEVI $4.45
- HALO $18.01
- P/E Ratio
- LEVI $19.88
- HALO $14.04
- Revenue Growth
- LEVI 7.23
- HALO 25.64
- 52 Week Low
- LEVI $12.17
- HALO $42.01
- 52 Week High
- LEVI $23.66
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- LEVI 54.96
- HALO 41.21
- Support Level
- LEVI $16.50
- HALO $53.54
- Resistance Level
- LEVI $17.84
- HALO $55.60
- Average True Range (ATR)
- LEVI 0.44
- HALO 1.24
- MACD
- LEVI -0.03
- HALO 0.09
- Stochastic Oscillator
- LEVI 79.93
- HALO 4.62
About LEVI Levi Strauss & Co
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.